TSA Exit Acceleration
A device exit needs the quality system first.
Fixed-fee scope to sequence the exit around the quality system, registrations, and traceability. Senior team on day one. The first conversation is always free.
A Medical Devices TSA exit is governed less by technology than by the regulated quality regime. The quality management system, device registrations, traceability, and vigilance processes dictate what can move, when, and to whom. Every move in it ties back to the broader TSA exit strategy a disciplined buyer runs.
In most carve-outs the long pole is systems. In medical devices it is the quality management system. A device maker cannot design, manufacture, or ship product without an operating, certified quality system that auditors and regulators recognize. During the TSA the seller often provides the quality system, the document control, and the certification umbrella. None of that transfers by flipping a switch.
The quality system is the gating item. Standing up the Newco's own certified system means more than installing software. It means design controls, document and record control, complaint handling, and the procedures that hold the certification, all operating and audited under the new entity. That standup depends on notified bodies and auditors the buyer does not control and cannot rush.
The buyer-side discipline is to start the quality system standup the day the deal signs, not when the TSA exit approaches. Certification audits take what they take, and a missed window can push a certificate by a full cycle, during which the Newco cannot ship under its own system. Every other workstream sequences behind this, because quality is what lets product reach patients.
The TSA often has to cover quality and regulatory services longer than a commercial carve-out would tolerate, because the seller's certified system cannot be replicated quickly. That extended dependency makes the commercial terms of those services unusually important. The buyer negotiates them knowing the quality standup sets the pace.
Device registrations and market approvals may name the seller as the legal manufacturer. The Newco needs registrations under its own name in every market it sells in, and a device without a valid registration cannot legally be sold there. The transfer of registrations is a regulated process that runs on different timelines in different jurisdictions, and it gates revenue market by market.
The buyer maps every registration, approval, and market authorization the portfolio depends on before the TSA clock matters. Each market has its own transfer process, and some require new submissions, fees, or local representation. A registration that lapses or fails to transfer in a key market stops sales there, so the buyer prioritizes the markets that carry the revenue.
Labeling and identifiers deserve attention. Device labels, instructions for use, and unique device identifiers may carry the seller's identity and registration details, and these have to be updated for the Newco. Like the registrations, labeling changes can require regulatory steps and lead time in production, so the buyer sequences labeling with the registration transfers.
The buyer-side move is to treat registration transfer as a critical path workstream that runs parallel to the quality standup. Each market authorization the business needs is checked against the Newco's ability to hold it in time. The diligence that supports this sits alongside the broader TSA exit strategy the buyer runs across the deal.
Device manufacturing runs on traceability: device history records, lot and serial tracking, and the linkage from raw material to finished product to the patient or facility that received it. A TSA exit that breaks traceability does not produce an error message. It degrades the ability to investigate a problem or run a recall, which is a patient safety and regulatory failure. Traceability is a constraint the exit protects.
The buyer validates that device history records, traceability links, and the distribution records that support recall all transfer to the Newco intact. Record integrity is the discipline. A migration that loses the linkage between a lot and where it shipped leaves the Newco unable to execute a targeted recall, and an untargeted recall is far more costly and damaging. The migration validates traceability end to end, not just data transfer.
Design and technical files deserve attention because they hold the evidence behind every registration. Design history files, technical documentation, and the supporting test records have to transfer cleanly so the Newco can defend its registrations in an audit. A registration the Newco cannot support with documentation is exposed the moment a regulator asks.
The buyer-side move is to treat traceability and technical records as a controlled migration with integrity checks at every step. The records that prove safety and support recall move together and are validated together, because in a regulated device business the records are not paperwork, they are the license to operate.
Complaint handling, adverse event reporting, and recall capability are regulated obligations that run continuously and cannot lapse for a moment. A device maker has reporting deadlines for adverse events, and a missed report during a transition is a regulatory violation regardless of the reason. The Newco has to run vigilance on its own systems from Day One, with the full complaint and event history carried forward.
The buyer ensures the complaint handling and vigilance processes transfer without a gap, including open complaints, ongoing investigations, and the reporting connections to regulators. The trap is treating vigilance as a back office process that can wait. An adverse event does not wait for the transition to finish, so the capability has to be live before the seller's process is switched off.
Post market surveillance deserves attention because it feeds the obligations that keep registrations valid. The data the Newco collects on field performance supports its regulatory standing, and a migration that breaks the surveillance pipeline leaves a gap in the evidence regulators expect. The buyer confirms surveillance continues uninterrupted through the transition.
The buyer-side move is to treat vigilance and complaint handling as a continuity workstream with no acceptable gap. Each regulated obligation is checked against the Newco's ability to meet it on the regulator's timeline. A device business is judged on how it handles problems, and the exit plan protects that capability above convenience.
The medical device exit sequence inverts the commercial playbook. Commercial carve-outs lead with systems and treat compliance as a workstream. Device carve-outs lead with the quality system, registrations, traceability, and vigilance, and treat systems as the thing that has to fit inside those constraints. The buyer who sequences the other way around risks patient safety and regulatory exposure.
Practically, the critical path runs through the quality system standup and registration transfers, then traceability and technical record migration validated for integrity, with vigilance carried forward without a gap. Pure back office separation is often the easiest part because it sits away from the regulated core.
The governance has to include quality and regulatory leadership, not just IT and finance. Decisions about cutover timing on a quality system are not purely technical. They involve registrations and patient safety. A governance structure that excludes quality and regulatory will commit to dates the business cannot keep. The exit plan is socialized with quality and regulatory leaders early.
Device carve-outs reward buyers who respect the constraints and punish those who treat them as friction. The quality standup takes what it takes. The registrations have to be in place. Vigilance cannot lapse. A buyer who plans the exit around those truths lands it. A buyer who plans around an idealized systems timeline pays the difference in regulatory risk, stopped sales, and extension fees.
The quality system and regulatory registrations set the constraints. The quality management system, device registrations, traceability, and complaint and vigilance processes all gate the exit. A cutover that breaks the quality system or loses traceability is a patient safety and compliance problem, not just an IT inconvenience.
A device maker cannot ship product without an operating quality management system that auditors and regulators recognize. If the seller provided the quality system and certification umbrella during the TSA, standing up the Newco's own certified system, including design controls and document control, is a gating workstream measured in months.
Device registrations and approvals may name the seller as the legal manufacturer. The Newco needs registrations under its own name in every market it sells in, and that transfer runs on regulator timelines that vary by jurisdiction. Selling a device without a valid registration is not an option, so it is a critical path workstream.
Complaint handling, adverse event reporting, and recall capability are regulated obligations that cannot lapse for a moment. The Newco must run these on its own systems from Day One, with full history carried forward, because a missed adverse event report is a regulatory and patient safety failure.
Where regulated quality systems and pharmacovigilance govern a life sciences exit.
Read the article →Where patient data and continuity of care govern a healthcare carve-out exit.
Read the article →Plant systems and supply chain continuity in an industrial carve-out exit.
Read the article →The 90-day governance, IT, finance, HR and procurement separation plan we run on live carve-outs. Get the playbook plus the bi-weekly Day One Letter — short, signal-heavy, buyer-side.
No spam. Unsubscribe in one click. · Read the overview first →
Fixed-fee scope to sequence the exit around the quality system, registrations, and traceability. Senior team on day one. The first conversation is always free.
Seven buyer-side moves to exit a Transition Services Agreement on time and below budget. The mark-up, the extension-fee curve, exit sequencing, and the 11-month calendar.
One tactic, one benchmark, or one pattern from a recent buyer-side engagement. Short. Signal heavy. Free.
Subscribe to The Day One Letter →